Our findings align with this vulnerability of EC and can serve as the base for treatments that restore iron balance, such as iron chelators, boosting HO-1, or ferroptosis inhibitors, might be especially effective in slowing disease progression in early AD patients with high CSF erythrocyte levels and PTAU. Here, HMOX1 is linked to Alzheimer disease.